Ultima Pharmaceuticals supplies this CJC 1295 peptide with DAC at 2 mg per vial, packaged in a 10 ml format for injection. The lyophilized powder requires reconstitution before use. Each vial delivers a fixed 2 mg dose of the modified peptide, distinguishing it from shorter-acting CJC 1295 variants that lack the Drug Affinity Complex attachment.

The company has operated from a USA base since 2022. Where other labs offer CJC 1295 DAC in 5 mg vials or smaller 2 ml containers, this 10 ml vial format holds 2 mg total, not per milliliter. The label specifies CJC 1295 with DAC, which extends the peptide's structure compared to standard CJC 1295 versions. Buyers weighing this against competing formats should note the total peptide content and vial volume when calculating value per dose.

The lyophilized form arrives as a white powder sealed under sterile conditions. Reconstitution with bacteriostatic water is required before the peptide solution is ready for subcutaneous or intramuscular administration. The 10 ml vial size provides handling room during reconstitution and withdrawal, reducing waste compared to smaller ampule formats that some laboratories use for the same 2 mg peptide load.